In the published article, there was an error in Table 2. The count of monoclonal antibodies used was interchanged during production between the different antibodies. The corrected Table 2 and its caption appear below.
Table 2
| Baseline characteristics | Patients, n = 22 (%) |
|---|---|
| irAE | |
| Grade 1 | 3 (13.6) |
| Grade 2 | 5 (22.7) |
| None | 14 (63.6) |
| Liver irAE | |
| Grade 1 | 2 (9.1) |
| Grade 2 | 1 (4.5) |
| Non–Liver irAE | |
| Colitis | 1 (4.5) |
| Pneumonitis | 1 (4.5) |
| Inflammatory arthritis | 1 (4.5) |
| Rash | 2 (9.1) |
| Treatment regimen before ICI# | |
| Mycophenolate mofetil | 1 (4.5) |
| Azathioprine | 4 (18.1) |
| Corticosteroids | 2 (9.1) |
| Methotrexate* | 1 (4.5) |
| UDCA | 9 (40.9) |
| Obeticholic acid | 1 (4.5) |
| No treatment for AILD | 7 (31.8) |
| Treatment adjustment during ICI therapy due to non-liver related events# | |
| Start Hydroxycholoroquine* | 1 (4.5) |
| Start or increase of corticosteroids | 2 (9.1) |
| No change in treatment | 16 (72.7) |
| Treatment adjustment during ICI therapy due to ILICI or AILD# | |
| Start or increase of corticosteroids | 2 (9.1) |
| Start UDCA | 1 (4.5) |
| Change from obeticholic acid to Fenofibrate | 1 (4.5) |
| Stop Azathioprine | 1 (4.5) |
| No change in treatment | 16 (72.7) |
| Monoclonal antibody used | |
| Atezolizumab | 7 (31.8) |
| Durvalumab | 5 (22.7) |
| Pembrolizumab | 4 (18.1) |
| Nivolumab | 4 (18.1) |
| Nivolumab + Ipilimumab | 1 (4.5) |
| Spartalizumab | 1 (4.5) |
Immune-related adverse events and immunosuppression.
No changes in immunosuppressive therapy were made before commencing ICI treatment to prevent potential irAEs. #Multiple treatments possible *Treatment for Rheumatoid arthritis.
The authors apologize for this error introduced during production and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Statements
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Summary
Keywords
autoimmune disease (AID), immune checkpoint inhibitors (ICI), autoimmune liver diseases (AILD), immune related adverse effects (irAEs), PD-1/PD-L1 immune checkpoint inhibitors, autoimmune hepatitis (AIH), primary sclerosing cholangites (PSC), primary biliary cholangitis (PBC)
Citation
Kocheise L, Piseddu I, Vonderlin J, Tjwa ET, Buescher G, Meunier L, Goeggelmann P, Fianchi F, Dumortier J, Barciela MR, Gevers TJG, Beretta-Piccoli BT, Londoño M-C, Frankova S, Roesner T, Joerg V, Schmidt C, Glaser F, Sutter JP, Fründt TW, Lohse AW, Huber S, von Felden J, Sebode M and Schulze K (2024) Corrigendum: PD-1/PD-L1 immune checkpoint therapy demonstrates favorable safety profile in patients with autoimmune and cholestatic liver disease. Front. Immunol. 15:1369747. doi: 10.3389/fimmu.2024.1369747
Received
12 January 2024
Accepted
15 January 2024
Published
24 January 2024
Volume
15 - 2024
Edited and reviewed by
Pascal Lapierre, University of Montreal Hospital Centre (CRCHUM), Canada
Updates
Copyright
© 2024 Kocheise, Piseddu, Vonderlin, Tjwa, Buescher, Meunier, Goeggelmann, Fianchi, Dumortier, Barciela, Gevers, Beretta-Piccoli, Londoño, Frankova, Roesner, Joerg, Schmidt, Glaser, Sutter, Fründt, Lohse, Huber, von Felden, Sebode and Schulze.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Lorenz Kocheise, l.kocheise@uke.de
†These authors have contributed equally to this work and share last authorship
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.